House dust mite allergy immunotherapy tablet - Stallergenes Greer plc

Drug Profile

House dust mite allergy immunotherapy tablet - Stallergenes Greer plc

Alternative Names: Actair; House dust mite allergy immunotherapy - Stallergenes Greer plc; House dust mite SLIT; House dust mite sublingual immunotherapy; Oralair Mites; S-524101; STAGR 320; STG 320

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Stallergenes SA
  • Developer Endo International; Shionogi; Stallergenes Greer plc
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Perennial allergic rhinitis
  • Registered Allergic asthma

Most Recent Events

  • 30 Mar 2017 Preregistration for Perennial allergic rhinitis (In children) in Japan (Sublingual)
  • 28 Mar 2017 Efficacy and adverse events data from a pivotal phase III trial Perennial allergic rhinitis in released by Stallergenes Greer
  • 15 Apr 2016 Phase-II clinical trials in Allergic asthma in USA (Sublingual) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top